We are live on ! Find out more
SGMO

SANGAMO THERAPEUTICS INC

Delisted

SGMO was delisted on the 4th of May, 2026.

197 hedge funds and large institutions have $911M invested in SANGAMO THERAPEUTICS INC in 2021 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 59 increasing their positions, 74 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

53% more call options, than puts

Call options by funds: $16.9M | Put options by funds: $11M

2.49% less ownership

Funds ownership: 55.46%52.97% (-2.5%)

3% less funds holding

Funds holding: 203197 (-6)

8% less capital invested

Capital invested by funds: $994M → $911M (-$82.9M)

20% less repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 74

22% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 23

Holders
197
Holders Change
-6
Holders Change %
-2.96%
% of All Funds
3.43%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
18
Increased
59
Reduced
74
Closed
23
Calls
$16.9M
Puts
$11M
Net Calls
+$5.86M
Net Calls Change
-$799K
Name Holding Trade Value Shares
Change
Change in
Stake
WA
1
Wasatch Advisors
Utah
$123M -$273K -24,128 -0.2%
BlackRock
2
BlackRock
New York
$117M -$45.8K -4,046 -0%
Vanguard Group
3
Vanguard Group
Pennsylvania
$109M -$193K -17,059 -0.2%
State Street
4
State Street
Massachusetts
$71.8M -$6.21M -548,501 -8%
CS
5
Credit Suisse
Switzerland
$43.1M +$88.5K +7,816 +0.2%
JP Morgan Chase
6
JP Morgan Chase
New York
$39.2M +$4.79M +422,964 +15%
Dimensional Fund Advisors
7
Dimensional Fund Advisors
Texas
$36M +$3.98M +351,101 +13%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$24.7M +$912K +80,576 +4%
Goldman Sachs
9
Goldman Sachs
New York
$18.6M -$4.3M -379,921 -20%
Northern Trust
10
Northern Trust
Illinois
$17.9M +$1.62M +143,240 +11%
N
11
Nuveen
North Carolina
$16.7M -$678K -59,903 -4%
LOAMS
12
Lombard Odier Asset Management (Switzerland)
Switzerland
$14.4M +$4.06M +358,512 +42%
Two Sigma Advisers
13
Two Sigma Advisers
New York
$12.2M -$4.33M -382,200 -27%
AC
14
Alexandria Capital
Virginia
$11.4M -$147K -12,978 -1%
Manulife (Manufacturers Life Insurance)
15
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$11.2M +$14.7K +1,299 +0.1%
Charles Schwab
16
Charles Schwab
California
$10.9M +$275K +24,290 +3%
Morgan Stanley
17
Morgan Stanley
New York
$10.7M +$2M +176,775 +25%
Invesco
18
Invesco
Georgia
$9.6M +$503K +44,410 +6%
Citadel Advisors
19
Citadel Advisors
Florida
$9.45M -$5.27M -465,554 -37%
RPAM
20
Rhenman & Partners Asset Management
Sweden
$9.16M
GLA
21
Great Lakes Advisors
Illinois
$8.28M -$30.5K -2,694 -0.4%
Wells Fargo
22
Wells Fargo
California
$8.26M +$354K +31,242 +5%
Nordea Investment Management
23
Nordea Investment Management
Sweden
$7.64M +$654K +57,722 +10%
SG Americas Securities
24
SG Americas Securities
New York
$7.42M +$5.95M +525,952 +563%
PAM
25
Panagora Asset Management
Massachusetts
$7.25M -$336K -29,671 -5%

SGMO Hedge Fund Activity: Q2 2021 in Review

197 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in SANGAMO THERAPEUTICS INC (SGMO) for Q2 2021, worth a combined $911M — down 8.3% from $994M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of SGMO and 18 opened new positions — a net loss of 5 holders — while 74 trimmed existing stakes and 59 added.

The largest buyer was SG Americas Securities, adding an estimated $5.95M. The largest seller was Compagnie Lombard Odier SCmA, cutting an estimated $9.61M.

  • 197 institutional investors held SANGAMO THERAPEUTICS INC (SGMO) as of Q2 2021, down from 203 in Q1 2021.
  • Funds reported $911M of SANGAMO THERAPEUTICS INC stock for Q2 2021, down 8.3% quarter-over-quarter.
  • 18 funds opened new SANGAMO THERAPEUTICS INC positions in Q2 2021 and 23 closed out, a net change of -5 holders.
  • The largest SANGAMO THERAPEUTICS INC buyer in Q2 2021 was SG Americas Securities, an estimated $5.95M added.
  • The largest SANGAMO THERAPEUTICS INC seller in Q2 2021 was Compagnie Lombard Odier SCmA, an estimated $9.61M sold.

Based on aggregated 13F filings for Q2 2021.